Epristeride
From Infogalactic: the planetary knowledge core
![]() |
|
Systematic (IUPAC) name | |
---|---|
17-(tert-butylcarbamoyl)androsta-3,5-diene-3-carboxylic acid
|
|
Clinical data | |
Legal status |
|
Routes of administration |
Oral |
Pharmacokinetic data | |
Bioavailability | 93%[1] |
Biological half-life | 26 hours[1] |
Identifiers | |
CAS Number | 119169-78-7 |
ATC code | None |
PubChem | CID: 68741 |
ChemSpider | 10625794 |
UNII | 39517A04PS |
ChEMBL | CHEMBL290823 |
Chemical data | |
Formula | C25H37NO3 |
Molecular mass | 399.566 g/mol |
|
|
|
Epristeride (SKF-105,657, ONO-9302) is a selective, transition state, non-competitive inhibitor of the type II isoform of the enzyme 5α-reductase,[2][3] similarly to finasteride and turosteride. It was under development for the treatment of benign prostatic hyperplasia and acne vulgaris by SmithKline Beecham (now GlaxoSmithKline), and reached phase III clinical trials in the United States, United Kingdom, and Japan,[2] but ultimately was never marketed.
See also
References
Categories:
- Chemical articles having calculated molecular weight overwritten
- Infobox drug articles without a structure image
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- Articles that show a Medicine navs template
- 5-alpha-reductase inhibitors
- Anti-acne preparations
- Carboxylic acids
- Dienes